GCCR ASO specifically reduced GCCR mRNA levels in liver and WAT from ZDF and HFD-STZ rats. Rats were dosed subcutaneously
with saline (□), GCCR ASO 37.5 mg/kg (▪), or control ASO 37.5 mg/kg ([cjs2112]) twice a week for 4 weeks. Total mRNA was prepared
from liver and WAT and analyzed for the expression of GCCR by RT-PCR (n = 8 per group for ZDF and n = 7 per group for HFD-STZ rats). Data are expressed as means ± SE relative to saline-treated rats. *P < 0.05, GCCR ASO treatment vs. saline treatment.